Projects per year
Personal profile
Education
- 2000 Ph.D., Graduate Institute of Pharmaceutical Sciences, National Taiwan University
- 1996 M.S., Graduate Institute of Pharmaceutical Sciences, National Taiwan University
- 1994 B.S., School of Pharmacy, Taipei Medical University
Experience
- 2021- Director, Research Center of Drug Discivery, Taipei Medical University
- 2018- Dean, College of Pharmacy, Taipei Medical University
- 2017- Director, Biomedical Commercialization Center, Taipei Medical University
- 2015-2022 Director, Research Center of Pharmaceutical Sciences and Biotechnology, College of Pharmacy, Taipei Medical University
- 2013-2017 Associate Dean, College of Pharmacy, Taipei Medical University
- 2012-2016 Director, Core Laboratory of Drug Organic Synthesis, Taipei Medical University
- 2013- Jointly Appointed Professor, Ph.D. Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University
- 2013- Jointly Appointed Professor, Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University
- 2012- Professor, School of Pharmacy, College of Pharmacy, Taipei Medical University
- 2008-2012 Associate Professor, School of Pharmacy, College of Pharmacy, Taipei Medical University
- 2004-2008 Assistant Professor, School of Pharmacy, College of Pharmacy, Taipei Medical University
- 2000-2004 Postdoctoral Research, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes
Awards
- 2019 Total Research project Budget Award - Excellence Award, Taipei Medical University
- 2019 Excellent Industry-Academia Collaboration Award, Taipei Medical University
1. EDITORIAL ADVISORY BOARD members, Journal of Medicinal Chemistry (IF = 6.259, CHEMISTRY/MEDICINAL)
2. 2015 Taipei Medical University Teaching Award
3. 2014 Taipei Biotech Awards, Gold “Industry-University Cooperation Award”
4. 2014 TienTe Lee Award, Young Scientist Award
5. 2011 Young scientist award, Ching-Kang Foundation for Pharmacy Promotion
Research Interests
- Discovery and Development of small molecular compounds towards IND
- Structure optimization through rational drug design and intelligent modification
- Medicinal Chemistry
Fingerprint
Dive into the research topics where Jing-Ping Liou is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Discovery of Bbb-Crossing Drugs Targeting Neuroinflammation for Glioblastoma( I )
8/1/22 → 7/31/23
Project: A - Government Institution › b - Ministry of Science and Technology
-
Organopalladium Assisted Stitching of Key Antitumor Fragments to Furnish Dual Inhibitory Anticancer Chemical Architectures( II )
8/1/22 → 7/31/23
Project: A - Government Institution › b - Ministry of Science and Technology
-
設計與合成雙效LSD1/HDAC抑制劑作為抗大腸直腸癌之研究
7/1/22 → 2/28/23
Project: A - Government Institution › b - Ministry of Science and Technology
-
代謝質體研究所引發的抗腦癌藥物研發
1/1/22 → 12/31/22
Project: A - Government Institution › f - Other (Funded by Government)
-
合成用於治療腦癌的前列腺素E2抑制劑
1/1/22 → 12/31/22
Project: B - Project of TMU › h - Higher Education Sprout Project
-
Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment
Wu, T. Y., Chen, M., Chen, I. C., Chen, Y. J., Chen, C. Y., Wang, C. H., Cheng, J. J., Nepali, K., Chuang, K. H. & Liou, J. P., Apr 2023, In: Journal of Advanced Research. 46, p. 159-171Research output: Contribution to journal › Article › peer-review
Open Access2 Citations (Scopus) -
Rationally designed donepezil-based hydroxamates modulate Sig-1R and HDAC isoforms to exert anti-glioblastoma effects
Nepali, K., Wu, A. C., Lo, W. L., Chopra, B., Lai, M. J., Chuang, J. Y. & Liou, J. P., Feb 2023, In: European Journal of Medicinal Chemistry. 248, 115054.Research output: Contribution to journal › Article › peer-review
-
2,6-Difluorobenzamide derivatives as store-operated calcium channel (SOC) inhibitors
Wang, Y. S., Yeh, T. K., Chang, W. C., Liou, J. P., Liu, Y. M. & Huang, W. C., Dec 5 2022, In: European Journal of Medicinal Chemistry. 243, 114773.Research output: Contribution to journal › Article › peer-review
-
Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier
Sharma, R., Chatterjee, E., Mathew, J., Sharma, S., Rao, N. V., Pan, C. H., Lee, S. B., Dhingra, A., Grewal, A. S., Liou, J. P., Guru, S. K. & Nepali, K., Oct 5 2022, In: European Journal of Medicinal Chemistry. 240, 114602.Research output: Contribution to journal › Article › peer-review
2 Citations (Scopus) -
A Potent Histone Deacetylase Inhibitor MPT0E028 Mitigates Emphysema Severity via Components of the Hippo Signaling Pathway in an Emphysematous Mouse Model
Yeh, L-Y., Fang, Y-T., Lee, H-S., Liu, C-H., Chen, Y-Y., Lo, Y-C., Laiman, V., Liou, J-P., Chung, K. F., Chuang, H-C. & Lin, C-H., May 2022, In: Frontiers in Medicine. 9, 794025.Research output: Contribution to journal › Article › peer-review
Open Access
Datasets
-
Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms
Lai, M. (Creator), Lee, C. (Creator), Chao, Y. (Creator), Mehndiratta, S. (Creator), Chen, M. (Creator), Liou, J. (Creator) & Lee, H. (Creator), Taylor & Francis, 2020
DOI: 10.6084/m9.figshare.13207104.v1, https://tandf.figshare.com/articles/journal_contribution/Effect_of_3-subsitution_of_quinolinehydroxamic_acids_on_selectivity_of_histone_deacetylase_isoforms/13207104/1
Dataset
-
Additional file 4: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M. (Contributor), Chang, L. (Contributor), Tu, H. (Contributor), Chang, C. (Contributor), Lai, M. (Contributor), Chen, Y. (Creator), Liou, J. (Creator), Teng, C. (Contributor) & Pan, S. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202896.v1, https://springernature.figshare.com/articles/Additional_file_4_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202896/1
Dataset
-
Additional file 1: of Suberoylanilide hydroxamic acid represses glioma stem-like cells
Chang, K. (Creator), Wang, J. (Creator), Chuang, J. (Creator), Ko, C. (Contributor), Hsu, T. (Contributor), Chang, W. (Creator), Yeh, S. (Contributor), Liou, J. (Creator), Liu, J. (Contributor) & Hsu, C. (Contributor), Figshare, 2016
DOI: 10.6084/m9.figshare.c.3596465_d1.v1, https://doi.org/10.6084%2Fm9.figshare.c.3596465_d1.v1
Dataset
-
Additional file 1: of The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells
Tu, H. (Contributor), Lin, Y. (Contributor), Chao, M. (Contributor), Sung, T. (Contributor), Wu, Y. (Contributor), Chen, Y. (Contributor), Lin, M. (Contributor), Liou, J. (Contributor), Pan, S. (Contributor) & Yang, C. (Contributor), Unknown Publisher, Dec 29 2018
DOI: 10.6084/m9.figshare.7531874.v1, https://springernature.figshare.com/articles/Additional_file_1_of_The_anticancer_effects_of_MPT0G211_a_novel_HDAC6_inhibitor_combined_with_chemotherapeutic_agents_in_human_acute_leukemia_cells/7531874/1
Dataset
-
The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells
Tu, H. (Contributor), Lin, Y. (Contributor), Chao, M. (Contributor), Sung, T. (Creator), Wu, Y. (Creator), Chen, Y. (Creator), Lin, M. (Contributor), Liou, J. (Creator), Pan, S. (Contributor) & Yang, C. (Contributor), Figshare, 2018
DOI: 10.6084/m9.figshare.c.4350887.v1, https://springernature.figshare.com/collections/The_anticancer_effects_of_MPT0G211_a_novel_HDAC6_inhibitor_combined_with_chemotherapeutic_agents_in_human_acute_leukemia_cells/4350887/1
Dataset